Prob not in short/medium term with expensive trial spend now...

Prob not in short/medium term with expensive trial spend now coming off they should have a few qtrs left so enough to get them through the upcoming phase 2 results for hay fever and bone bruising, which will be major re-rate events, in which case instos will be throwing money at them!

today's share price move prob explained by Equity Story writing them up today as buy of the month and calling them a Disallowed from here on positive hay fever results!!

On the 19th of May 2017 Equity Story would like to share a new Story of the Month - Paradigm Biopharmaceuticals Ltd (PAR) revolving around a potential new treatment for Hay Fever. With Phase II Trials nearing completion the following bullet points summarise the story.
* New multi-acting, single application (non steroid) treatment for hay fever * First to market advantage * Addresses the safety issue of the dosing of children with steroids. Continued administration of steroids to children may effect their growth. Steroids also suppress the immune system paving the way for other infections to arise. * Addressable market of 600 million hay fever sufferers with expected market size of US$11B * Dymista looks to be the closest direct competitor (NB: Dymista contains cortisteroid). 2015 sales ~US$118 million. * Two other major programs well underway exploring its use in treating: 1. Bone Bruising (Bone Marrow Edema), Phase IIa open label clinical trial 2. Alphavirus (Ross River and Chikungunya virus - viral arthritis), plans to enter Phase II clinical trial shortly.
We encourage you to take a look at our Story of the Month Paradigm Biopharmaceuticals (PAR) @ 60c - Mkt cap $61M. The report can be read HERE.

Currently the team at Equity Story are following the story and are very excited with where it is right now. They seem to be progressing very well but would prefer to wait for the Phase II Hay Fever clinical trial results before recommending this stock as a potential Disallowed. We recommend to keep PAR on your watchlist as this could be game-changing in the Hay Fever space which alone has an addressable market of US$11B